pharma · Duchenne Muscular Dystrophy · Muscular Dystrophy, Duchenne · SRPT
Sarepta Therapeutics
Sarepta Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SRPT. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophy, Duchenne, Duche
215 First Street, Cambridge, MA 02142, US HQ
1,150 Employees
Public company Type
SRPT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 215 First Street, Cambridge, MA 02142, US
- Employees
- 1,150
- Programs
- 46
- Drugs
- 23
- Patents
- 102
4045-301
Phase 3 · small molecule · Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.
4045-301 for Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping. is a Phase 3 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 4045-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sarepta Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.
- Status
- active
- Trials
- 1